Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer

Hepatopancreatobiliary Surgery Institute of Gansu Province168 enrolled

Overview

This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection.

Serum uric acid is a risk factor for gallbladder cancer in men and has a strong effect on pancreatic cancer in women. It has also been shown that elevated intracellular serum uric acid can induce an inflammatory stress response, which may promote its transformation, while elevated extracellular serum uric acidy further stimulate tumor cell proliferation, migration, and survival, and promote the development of highly aggressive cancer. In this study, the changes of serum uric acid before and after surgery was used as a prognostic marker for the survival of pancreatic cancer patients.

Study Type

OBSERVATIONAL

Enrollment

168

Conditions

Serum Uric Acid

Interventions

serum uric acid testDIAGNOSTIC_TEST

Detect the serum uric acid in blood sample

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with pathologically confirmed pancreatic cancer (primary) * Patients who underwent Radical resection of pancreatic cancer（Pancreaticoduodenectomy or Distal pancreatectomy） * The postoperative survival time was at least 6 weeks Exclusion Criteria: * No surgery was performed, or only palliative surgery/ biopsy was performed * Patients who underwent emergency hemodialysis or plasma exchange after surgery * History of gout or long-term urate-lowering therapy, such as allopurinol * Patients are missing follow-up data * Hydrochlorothiazide and furosemide were used * Chronic kidney disease * Oncolytic syndrome * Hemolytic anemia * Lead poisoning * Hyperparathyroidism * Hypothyroidism * A tyrosinase inhibitor was used * Patients with nonpancreatic primary tumors * Pregnant or postpartum women.

Locations (1)

Hepatopancreatobiliary Surgery Institute of Gansu Province

Lanzhou, Gansu, China

RECRUITING

Outcomes

Primary Outcomes

Overall survival

Overall survival was defined as the time from diagnosis to death.

Time frame: 3-5 years

Secondary Outcomes

Recurrence-free survival

Recurrence-free survival is the length of time from either the date of diagnosis or the start of therapy for a disease to the date of the first loco-regional or systemic recurrence.

Time frame: 3-5 years

Cost of hospitalization

The cost of the first hospitalization from admission to discharge.

Time frame: 3 months

Length of hospital stay

The first day of hospitalization for the first admission to the last day of discharge.

Time frame: 3 months

Pancreatic fistula

Whether or not pancreatic-intestinal anastomotic leakage occurred at the time of the first hospitalization.

Time frame: 3 months

Biliary fistula

Whether or not a biliary-intestinal anastomotic leak occurred at the time of the first hospitalization.

Time frame: 3 months

Bleeding

Whether or not there was bleeding after the first inpatient surgery.

Time frame: 3 months

Abdominal cavity infection

Whether or not there was an abdominal infection after the first inpatient surgery.

Time frame: 3 months

Central Contacts

Wenbo Meng, M.D. Ph. D.

CONTACT

13919177177 mengwb@163.com

Zhengping An, M.D.

CONTACT

18298415512 anzhp2023@lzu.edu.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.